Show simple item record

dc.contributor.authorBozkurt, Bulent
dc.contributor.authorOzol, Duygu
dc.contributor.authorUysal, Sema
dc.contributor.authorYildirim, Zeki
dc.contributor.authorArmutcu, FERAH
dc.contributor.authorAKGEDIK, Recep
dc.contributor.authorAKGEDIK, Sukran
dc.contributor.authorKARAMANLI, Harun
dc.date.accessioned2021-03-03T20:07:24Z
dc.date.available2021-03-03T20:07:24Z
dc.date.issued2012
dc.identifier.citationAKGEDIK R., AKGEDIK S., KARAMANLI H., Uysal S., Bozkurt B., Ozol D., Armutcu F., Yildirim Z., "Effect of Resveratrol on Treatment of Bleomycin-Induced Pulmonary Fibrosis in Rats", INFLAMMATION, cilt.35, sa.5, ss.1732-1741, 2012
dc.identifier.issn0360-3997
dc.identifier.otherav_5837987c-76a4-42bd-9cb7-ba4fb54c9160
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/62129
dc.identifier.urihttps://doi.org/10.1007/s10753-012-9491-0
dc.description.abstractResveratrol has a preventive potential on bleomycin-induced pulmonary fibrosis in prophylactic use; however, it was not studied in the treatment of the fibrosis. This study investigated the role of resveratrol on the treatment of bleomycin-induced pulmonary fibrosis. Intratracheal bleomycin (2.5 mg/kg) was given in fibrosis groups and saline in controls. First dose of resveratrol was given 14 days after bleomycin and continued until sacrifice. On 29th day, fibrosis in lung was estimated by Aschoft's criteria and hydroxyproline content. Bleomycine increased the fibrosis score (3.70 +/- 1.04) and hydroxyproline levels (4.99 +/- 0.90 mg/g tissue) as compared to control rats (1.02 +/- 0.61 and 1.88 +/- 0.59 mg/g), respectively. These were reduced to 3.16 +/- 1.58 (P = 0.0001) and 3.08 +/- 0.73 (P > 0.05), respectively, by resveratrol. Tissue malondialdehyde levels in the bleomycin-treated rats were higher (0.55 +/- 0.22 nmol/mg protein) than that of control rats (0.16 +/- 0.07; P = 0.0001) and this was reduced to 0.16 +/- 0.06 by resveratrol (P = 0.0001). Tissue total antioxidant capacity is reduced (0.027 +/- 0.01) by bleomycine administration when compared control rats (0.055 +/- 0.012 mmol Trolox Equiv/mg protein; P = 0.0001) and increased to 0.041 +/- 0.008 (P = 0.001) by resveratrol. We concluded that resveratrol has some promising potential on the treatment of bleomycin-induced pulmonary fibrosis in rats. However, different doses of the drug should be further studied.
dc.language.isoeng
dc.subjectSağlık Bilimleri
dc.subjectMoleküler Biyoloji ve Genetik
dc.subjectYaşam Bilimleri
dc.subjectHistoloji-Embriyoloji
dc.subjectTemel Tıp Bilimleri
dc.subjectTıp
dc.subjectHÜCRE BİYOLOJİSİ
dc.subjectMoleküler Biyoloji ve Genetik
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectİmmünoloji
dc.subjectTemel Bilimler
dc.titleEffect of Resveratrol on Treatment of Bleomycin-Induced Pulmonary Fibrosis in Rats
dc.typeMakale
dc.relation.journalINFLAMMATION
dc.contributor.departmentOrdu State Hospital , ,
dc.identifier.volume35
dc.identifier.issue5
dc.identifier.startpage1732
dc.identifier.endpage1741
dc.contributor.firstauthorID95130


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record